Albenatide vs Semaglutide (Ozempic)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

Albenatide

Developed by ConjuChem and partners

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT07058545 · Phase 3 · completed

The study randomized 474 participants to CJC-1134-PC or placebo and blinded participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in HbA1c at Week 25, a surrogate measure, and the registry does not report whether the comparison was favorable or statistically significant.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No aligned efficacy figure on record for this race.

Semaglutide (Ozempic)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01720446 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (From Week 0 up to Week 234): Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003. (met)

Result source: NCT03819153

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlbenatideSemaglutide (Ozempic)
HbA1c, change-0.8% vs -0.5%−0.4 vs placebo1.5 mg · wk 12.14 · n 44NCT00638716
1 other result
  • -1.3% vs -0.3% 1.5 mg · wk 12.14 · n 27 · Phase 2 · primary NCT00674466
-1.6% vs 0%−1.6 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
35 other results
  • -1.9% vs -0.1% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · primary NCT02305381
  • -1.6% vs -0.2% 1.0 mg weekly · wk 30 · n 151 · Phase 3 · primary NCT03086330
  • -1.5% vs 0% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · primary NCT02054897
  • -1.4% vs -0.1% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · primary NCT02305381
  • -1.5% vs -0.9% 1.0 mg · wk 56 · n 404 · Phase 3 · primary NCT01885208
  • -1.6% vs -0.6% 1.0 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.8% vs -1.1% 1.0 mg · wk 40 · n 300 · Phase 3 · primary NCT02648204
  • -1.6% vs -0.8% 1.0 mg/week · wk 30 · n 360 · Phase 3 · primary NCT02128932
  • -1.7% vs -1.1% 1.0 mg · wk 30 · n 290 · Phase 3 · primary NCT03191396
  • -1.3% vs -0.6% 0.5 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.5% vs -1.1% 0.5 mg · wk 40 · n 301 · Phase 3 · primary NCT02648204
  • -1.2% vs -0.8% 0.5 mg/week · wk 30 · n 362 · Phase 3 · primary NCT02128932
  • -1.5% vs -1.2% wk 52 · n 795 · Phase 3 · primary NCT03689374
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · primary NCT05514535
  • -1.4% vs -0.4% 1.0 mg · wk 104 · n 822 · Phase 3 · secondary NCT01720446
  • -1.1% vs -0.4% 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -0.9% vs -0.0% wk 104 · n 1448 · Phase 3 · secondary NCT03819153
  • -1.8% vs -0.3% 7.2 mg · wk 72 · n 288 · Phase 3 · secondary NCT05649137
  • -0.8% vs 0.2% wk 52 · n 304 · Phase 3 · secondary NCT04560998
  • -2.0% vs -0.7% 1.0 mg · wk 56 · n 204 · Phase 3 · secondary NCT02207374
  • -2.2% vs -0.7% 1.0 mg · wk 30 · n 102 · Phase 3 · secondary NCT02254291
  • -1.7% vs -0.7% 0.5 mg · wk 56 · n 220 · Phase 3 · secondary NCT02207374
  • -1.9% vs -0.7% 0.5 mg · wk 30 · n 103 · Phase 3 · secondary NCT02254291
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · secondary NCT05514535
  • -1.9% vs -1.1% 2.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.1% vs -0.4% 21.6 mg · wk 34 · n 59 · Phase 2 · primary NCT05144984
  • -2.1% vs -1.1% 16.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.8% vs -1.1% 8.0 mg · wk 40 · n 57 · Phase 2 · primary NCT05486065
  • -2.3% vs -0.4% 2.4 mg + 2.4 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 7.2 mg · wk 34 · n 74 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 12.0 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.3% vs -0.4% 2.4 mg + 21.6 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • -1.4% vs -1.0% wk 104 · n 374 · Phase 4 · secondary NCT03596450
  • -1.5% vs -1.1% wk 52 · n 430 · Phase 4 · secondary NCT03596450
Body weight, change (kg)-2.0 vs -1.6−0.4 vs placebo1.5 mg · wk 12.14 · n 44NCT00638716
1 other result
  • -1.2 vs -0.4 1.5 mg · wk 12.14 · n 27 · Phase 2 · secondary NCT00674466
-4.9 vs -0.6−4.3 vs placebo1.0 mg · wk 104 · n 822NCT01720446
32 other results
  • -3.6 vs -0.6 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -5.5 vs -1.4 wk 104 · n 1502 · Phase 3 · secondary NCT03819153
  • -4.7 vs -0.9 1.0 mg weekly · wk 30 · n 130 · Phase 3 · secondary NCT02054897
  • -6.4 vs -1.4 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -4.7 vs -1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -3.7 vs -0.9 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • -3.7 vs -1.4 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -14.9 vs -4.6 7.2 mg · wk 72 · n 291 · Phase 3 · secondary NCT05649137
  • -5.2 vs -1.2 wk 52 · n 310 · Phase 3 · secondary NCT04560998
  • -5.6 vs -1.9 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -6.1 vs -1.9 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -6.5 vs -2.3 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • -5.2 vs 1.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -5.8 vs -2 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -4.3 vs -1.9 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -3.5 vs 1.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -4.2 vs 2.9 wk 52 · n 801 · Phase 3 · secondary NCT03689374
  • -4.2 vs -0.4 1.0 mg weekly · wk 30 · n 239 · Phase 3 · secondary NCT03061214
  • -4.6 vs -2.3 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • -3 vs -0.4 0.5 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -5.7 vs -4.3 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -8.0 vs 0.4 wk 40 · n 282 · Phase 3 · secondary NCT05514535
  • -8.9 vs -2.3 2.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -4.7 vs -2.6 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -13.1 vs -2.3 16.0 mg · wk 40 · n 55 · Phase 2 · secondary NCT05486065
  • -10.1 vs -2.3 8.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -8.9 vs -2.6 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 7.2 mg · wk 34 · n 60 · Phase 2 · secondary NCT05144984
  • -10 vs -2.6 2.4 mg + 12.0 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 21.6 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -5 vs -3.1 wk 104 · n 389 · Phase 4 · secondary NCT03596450
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
HbA1c below 7%—Not posted · NCT0705727172.3% vs 24.8%+47.5 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
10 other results
  • 78.6% vs 10.5% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • 82.5% vs 20.5% 1.0 mg weekly · wk 30 · n 120 · Phase 3 · secondary NCT03086330
  • 74.2% vs 24.8% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • 60.6% vs 10.5% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • 78.7% vs 52.2% 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • 84% vs 49.6% 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • 80.4% vs 45.9% 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • 68.4% vs 52.2% 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • 74.5% vs 49.6% 0.5 mg weekly · wk 30 · n 235 · Phase 3 · secondary NCT03061214
  • 76.1% vs 50.8% wk 52 · n 293 · Phase 3 · secondary NCT03136484
Fasting plasma glucose, change-0.8 vs -0.6−0.2 vs placebo1.5 mg · wk 12.14 · n 42NCT00638716
1 other result
  • -0.3 vs 0.7 1.5 mg · wk 12.14 · n 27 · Phase 2 · secondary NCT00674466
-2.1 vs -0.9−1.2 vs placebo1.0 mg · wk 104 · n 822NCT01720446
24 other results
  • -1.8 vs -0.9 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -2.4 vs -0.6 1.0 mg weekly · wk 30 · n 129 · Phase 3 · secondary NCT02054897
  • -2.4 vs -0.5 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -2.3 vs 0.1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -2.4 vs -0.6 0.5 mg weekly · wk 30 · n 125 · Phase 3 · secondary NCT02054897
  • -1.6 vs -0.5 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -3.3 vs -1.1 7.2 mg · wk 72 · n 281 · Phase 3 · secondary NCT05649137
  • -2.8 vs -2 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -2.6 vs -1.1 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.8 vs -1.9 1.0 mg · wk 40 · n 299 · Phase 3 · secondary NCT02648204
  • -2.7 vs -2.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -2.6 vs -1 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -2.6 vs -1.5 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -2.1 vs -1.1 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.2 vs -1.9 0.5 mg · wk 40 · n 298 · Phase 3 · secondary NCT02648204
  • -2.0 vs -2.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -1.3 vs -0.8 wk 52 · n 770 · Phase 3 · secondary NCT03689374
  • -2.2 vs -1 0.5 mg weekly · wk 30 · n 237 · Phase 3 · secondary NCT03061214
  • -2.5 vs -2 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -1.4 vs -0.1 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -3.9 vs -0.1 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -3.4 vs -0.1 2.4 mg + 7.2 mg · wk 34 · n 58 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 12.0 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 21.6 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
3-point MACE (% with event)—Not posted · NCT070572716.6% vs 8.9%−2.3 vs placebon 1648NCT01720446
1 other result
  • 12% vs 14.4% n 1767 · Phase 3 · secondary NCT03819153

HbA1c, change

Albenatide
-0.8% vs -0.5%−0.4 vs placebo1.5 mg · wk 12.14 · n 44NCT00638716
1 other result
  • -1.3% vs -0.3% 1.5 mg · wk 12.14 · n 27 · Phase 2 · primary NCT00674466
Semaglutide (Ozempic)
-1.6% vs 0%−1.6 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
35 other results
  • -1.9% vs -0.1% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · primary NCT02305381
  • -1.6% vs -0.2% 1.0 mg weekly · wk 30 · n 151 · Phase 3 · primary NCT03086330
  • -1.5% vs 0% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · primary NCT02054897
  • -1.4% vs -0.1% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · primary NCT02305381
  • -1.5% vs -0.9% 1.0 mg · wk 56 · n 404 · Phase 3 · primary NCT01885208
  • -1.6% vs -0.6% 1.0 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.8% vs -1.1% 1.0 mg · wk 40 · n 300 · Phase 3 · primary NCT02648204
  • -1.6% vs -0.8% 1.0 mg/week · wk 30 · n 360 · Phase 3 · primary NCT02128932
  • -1.7% vs -1.1% 1.0 mg · wk 30 · n 290 · Phase 3 · primary NCT03191396
  • -1.3% vs -0.6% 0.5 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.5% vs -1.1% 0.5 mg · wk 40 · n 301 · Phase 3 · primary NCT02648204
  • -1.2% vs -0.8% 0.5 mg/week · wk 30 · n 362 · Phase 3 · primary NCT02128932
  • -1.5% vs -1.2% wk 52 · n 795 · Phase 3 · primary NCT03689374
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · primary NCT05514535
  • -1.4% vs -0.4% 1.0 mg · wk 104 · n 822 · Phase 3 · secondary NCT01720446
  • -1.1% vs -0.4% 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -0.9% vs -0.0% wk 104 · n 1448 · Phase 3 · secondary NCT03819153
  • -1.8% vs -0.3% 7.2 mg · wk 72 · n 288 · Phase 3 · secondary NCT05649137
  • -0.8% vs 0.2% wk 52 · n 304 · Phase 3 · secondary NCT04560998
  • -2.0% vs -0.7% 1.0 mg · wk 56 · n 204 · Phase 3 · secondary NCT02207374
  • -2.2% vs -0.7% 1.0 mg · wk 30 · n 102 · Phase 3 · secondary NCT02254291
  • -1.7% vs -0.7% 0.5 mg · wk 56 · n 220 · Phase 3 · secondary NCT02207374
  • -1.9% vs -0.7% 0.5 mg · wk 30 · n 103 · Phase 3 · secondary NCT02254291
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · secondary NCT05514535
  • -1.9% vs -1.1% 2.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.1% vs -0.4% 21.6 mg · wk 34 · n 59 · Phase 2 · primary NCT05144984
  • -2.1% vs -1.1% 16.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.8% vs -1.1% 8.0 mg · wk 40 · n 57 · Phase 2 · primary NCT05486065
  • -2.3% vs -0.4% 2.4 mg + 2.4 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 7.2 mg · wk 34 · n 74 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 12.0 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.3% vs -0.4% 2.4 mg + 21.6 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • -1.4% vs -1.0% wk 104 · n 374 · Phase 4 · secondary NCT03596450
  • -1.5% vs -1.1% wk 52 · n 430 · Phase 4 · secondary NCT03596450

Body weight, change (kg)

Albenatide
-2.0 vs -1.6−0.4 vs placebo1.5 mg · wk 12.14 · n 44NCT00638716
1 other result
  • -1.2 vs -0.4 1.5 mg · wk 12.14 · n 27 · Phase 2 · secondary NCT00674466
Semaglutide (Ozempic)
-4.9 vs -0.6−4.3 vs placebo1.0 mg · wk 104 · n 822NCT01720446
32 other results
  • -3.6 vs -0.6 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -5.5 vs -1.4 wk 104 · n 1502 · Phase 3 · secondary NCT03819153
  • -4.7 vs -0.9 1.0 mg weekly · wk 30 · n 130 · Phase 3 · secondary NCT02054897
  • -6.4 vs -1.4 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -4.7 vs -1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -3.7 vs -0.9 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • -3.7 vs -1.4 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -14.9 vs -4.6 7.2 mg · wk 72 · n 291 · Phase 3 · secondary NCT05649137
  • -5.2 vs -1.2 wk 52 · n 310 · Phase 3 · secondary NCT04560998
  • -5.6 vs -1.9 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -6.1 vs -1.9 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -6.5 vs -2.3 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • -5.2 vs 1.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -5.8 vs -2 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -4.3 vs -1.9 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -3.5 vs 1.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -4.2 vs 2.9 wk 52 · n 801 · Phase 3 · secondary NCT03689374
  • -4.2 vs -0.4 1.0 mg weekly · wk 30 · n 239 · Phase 3 · secondary NCT03061214
  • -4.6 vs -2.3 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • -3 vs -0.4 0.5 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -5.7 vs -4.3 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -8.0 vs 0.4 wk 40 · n 282 · Phase 3 · secondary NCT05514535
  • -8.9 vs -2.3 2.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -4.7 vs -2.6 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -13.1 vs -2.3 16.0 mg · wk 40 · n 55 · Phase 2 · secondary NCT05486065
  • -10.1 vs -2.3 8.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -8.9 vs -2.6 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 7.2 mg · wk 34 · n 60 · Phase 2 · secondary NCT05144984
  • -10 vs -2.6 2.4 mg + 12.0 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 21.6 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -5 vs -3.1 wk 104 · n 389 · Phase 4 · secondary NCT03596450
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352

HbA1c below 7%

Albenatide
—Not posted · NCT07057271
Semaglutide (Ozempic)
72.3% vs 24.8%+47.5 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
10 other results
  • 78.6% vs 10.5% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • 82.5% vs 20.5% 1.0 mg weekly · wk 30 · n 120 · Phase 3 · secondary NCT03086330
  • 74.2% vs 24.8% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • 60.6% vs 10.5% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • 78.7% vs 52.2% 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • 84% vs 49.6% 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • 80.4% vs 45.9% 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • 68.4% vs 52.2% 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • 74.5% vs 49.6% 0.5 mg weekly · wk 30 · n 235 · Phase 3 · secondary NCT03061214
  • 76.1% vs 50.8% wk 52 · n 293 · Phase 3 · secondary NCT03136484

Fasting plasma glucose, change

Albenatide
-0.8 vs -0.6−0.2 vs placebo1.5 mg · wk 12.14 · n 42NCT00638716
1 other result
  • -0.3 vs 0.7 1.5 mg · wk 12.14 · n 27 · Phase 2 · secondary NCT00674466
Semaglutide (Ozempic)
-2.1 vs -0.9−1.2 vs placebo1.0 mg · wk 104 · n 822NCT01720446
24 other results
  • -1.8 vs -0.9 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -2.4 vs -0.6 1.0 mg weekly · wk 30 · n 129 · Phase 3 · secondary NCT02054897
  • -2.4 vs -0.5 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -2.3 vs 0.1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -2.4 vs -0.6 0.5 mg weekly · wk 30 · n 125 · Phase 3 · secondary NCT02054897
  • -1.6 vs -0.5 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -3.3 vs -1.1 7.2 mg · wk 72 · n 281 · Phase 3 · secondary NCT05649137
  • -2.8 vs -2 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -2.6 vs -1.1 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.8 vs -1.9 1.0 mg · wk 40 · n 299 · Phase 3 · secondary NCT02648204
  • -2.7 vs -2.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -2.6 vs -1 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -2.6 vs -1.5 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -2.1 vs -1.1 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.2 vs -1.9 0.5 mg · wk 40 · n 298 · Phase 3 · secondary NCT02648204
  • -2.0 vs -2.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -1.3 vs -0.8 wk 52 · n 770 · Phase 3 · secondary NCT03689374
  • -2.2 vs -1 0.5 mg weekly · wk 30 · n 237 · Phase 3 · secondary NCT03061214
  • -2.5 vs -2 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -1.4 vs -0.1 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -3.9 vs -0.1 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -3.4 vs -0.1 2.4 mg + 7.2 mg · wk 34 · n 58 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 12.0 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 21.6 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984

3-point MACE (% with event)

Albenatide
—Not posted · NCT07057271
Semaglutide (Ozempic)
6.6% vs 8.9%−2.3 vs placebon 1648NCT01720446
1 other result
  • 12% vs 14.4% n 1767 · Phase 3 · secondary NCT03819153
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Albenatide: 3 of 4 rows · Semaglutide (Ozempic): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlbenatideSemaglutide (Ozempic)
Dropout rate
14%1.5 mga
NCT00638716 · Phase 2 · registry result, not featured evidence
show 1 more result
23.3%1.5 mg
NCT00674466 · Phase 2 · registry result, not featured evidence
1.3%1.0 mgb
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
1.7%0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.9%1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.4%
NCT03819153 · Phase 3
5.4%1.0 mg weekly
NCT02054897 · Phase 3
7.8%0.5 mg weekly
NCT02054897 · Phase 3
5.1%1.0 mg weekly
NCT01930188 · Phase 3 · combination
5.4%0.5 mg weekly
NCT01930188 · Phase 3 · combination
5.3%1.0 mg/week
NCT02128932 · Phase 3
7.5%0.5 mg/week
NCT02128932 · Phase 3
3.8%2.0 mg weekly
NCT03989232 · Phase 3
2.1%1.0 mg weekly
NCT03989232 · Phase 3
3.8%1.0 mg weekly
NCT02305381 · Phase 3
3.8%0.5 mg weekly
NCT02305381 · Phase 3
0%
NCT04126603 · Phase 4 · registry result, not featured evidence
0%
NCT05786521 · Phase 4 · registry result, not featured evidence
10.6%
NCT05533632 · Phase 4 · registry result, not featured evidence
0%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
28.1%
NCT03596450 · Phase 4 · registry result, not featured evidence
36.5%Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
1.7%Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
3.9%7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
18.3%1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
7.6%
NCT04560998 · Phase 3 · registry result, not featured evidence
1.5%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—
NCT03689374 · Phase 3 · registry result, not featured evidence
9.7%1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
8.7%0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
6.9%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
1%1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
2.6%1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
7%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
7.3%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
4.1%1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2.5%0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2.9%1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
0%0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
8.2%2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
11.3%16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
12.9%8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.4%21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
3.9%2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
3.9%2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
3.9%2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.7%2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—1.5 mga
NCT00638716 · Phase 2 · registry result, not featured evidence
show 1 more result
—1.5 mg
NCT00674466 · Phase 2 · registry result, not featured evidence
—1.0 mgb
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
—0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT03819153 · Phase 3
—1.0 mg weekly
NCT02054897 · Phase 3
—0.5 mg weekly
NCT02054897 · Phase 3
—1.0 mg weekly
NCT01930188 · Phase 3 · combination
—0.5 mg weekly
NCT01930188 · Phase 3 · combination
—1.0 mg/week
NCT02128932 · Phase 3
—0.5 mg/week
NCT02128932 · Phase 3
—2.0 mg weekly
NCT03989232 · Phase 3
—1.0 mg weekly
NCT03989232 · Phase 3
—1.0 mg weekly
NCT02305381 · Phase 3
—0.5 mg weekly
NCT02305381 · Phase 3
—
NCT04126603 · Phase 4 · registry result, not featured evidence
—
NCT05786521 · Phase 4 · registry result, not featured evidence
3.8%
NCT05533632 · Phase 4 · registry result, not featured evidence
—once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
2.2%
NCT03596450 · Phase 4 · registry result, not featured evidence
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
—
NCT04560998 · Phase 3 · registry result, not featured evidence
—
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—
NCT03689374 · Phase 3 · registry result, not featured evidence
—1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
—0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
—
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
—1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
—1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
0%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
0%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
—2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
—2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
0%1.5 mga
NCT00638716 · Phase 2 · registry result, not featured evidence
show 1 more result
3.3%1.5 mg
NCT00674466 · Phase 2 · registry result, not featured evidence
33.6%1.0 mgb
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
35%0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
9.4%1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
49.6%
NCT03819153 · Phase 3
5.4%1.0 mg weekly
NCT02054897 · Phase 3
5.5%0.5 mg weekly
NCT02054897 · Phase 3
7.3%1.0 mg weekly
NCT01930188 · Phase 3 · combination
7.3%0.5 mg weekly
NCT01930188 · Phase 3 · combination
4.7%1.0 mg/week
NCT02128932 · Phase 3
6.1%0.5 mg/week
NCT02128932 · Phase 3
4.4%2.0 mg weekly
NCT03989232 · Phase 3
5.2%1.0 mg weekly
NCT03989232 · Phase 3
9.2%1.0 mg weekly
NCT02305381 · Phase 3
6.1%0.5 mg weekly
NCT02305381 · Phase 3
0%
NCT04126603 · Phase 4 · registry result, not featured evidence
0%
NCT05786521 · Phase 4 · registry result, not featured evidence
1%
NCT05533632 · Phase 4 · registry result, not featured evidence
22.5%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
6%
NCT03596450 · Phase 4 · registry result, not featured evidence
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.2%Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
5.9%INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
9.8%7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
19.7%1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
18.7%
NCT04560998 · Phase 3 · registry result, not featured evidence
6.2%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
7.4%
NCT03689374 · Phase 3 · registry result, not featured evidence
6.6%1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
6.3%0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
4.6%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
5.9%1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
4.7%1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
7.7%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
5.6%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
5%1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
7.9%0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2%1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
5.8%0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
6.7%2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
1.6%16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.3%8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.4%21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
2.6%2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
7.8%2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
6.5%2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
4.1%2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
1.5 mga
nausea 22.4% (placebo 15.8%)
diarrhea 12.2% (placebo 5.3%)
vomiting 12.2% (placebo 3.5%)
NCT00638716 · Phase 2 · registry result, not featured evidence
show 1 more result
1.5 mg
headache 26.7% (placebo 24.1%)
nausea 26.7% (placebo 13.8%)
vomiting 23.3% (placebo 17.2%)
NCT00674466 · Phase 2 · registry result, not featured evidence
1.0 mgb
nausea 21.8% (placebo 7.5%)
diarrhoea 18% (placebo 11.8%)
vomiting 14.8% (placebo 5.1%)
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 42 more results
0.5 mg
diarrhoea 17.9% (placebo 11.8%)
nausea 17.3% (placebo 7.5%)
lipase increased 11.4% (placebo 8%)
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
1.0 mg
nausea 22.3%
diarrhoea 11.4%
lipase increased 10.1%
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
diabetic retinopathy 19.2% (placebo 18.4%)
covid-19 12.5% (placebo 13.9%)
NCT03819153 · Phase 3
1.0 mg weekly
nausea 23.8% (placebo 7.8%)
diarrhoea 10.8% (placebo 2.3%)
headache 6.9% (placebo 6.2%)
NCT02054897 · Phase 3
0.5 mg weekly
nausea 20.3% (placebo 7.8%)
diarrhoea 12.5% (placebo 2.3%)
headache 11.7% (placebo 6.2%)
NCT02054897 · Phase 3
1.0 mg weekly
nausea 17.6%
diarrhoea 13%
vomiting 10%
NCT01930188 · Phase 3 · combination
0.5 mg weekly
nausea 17.8%
diarrhoea 13%
nasopharyngitis 12.2%
NCT01930188 · Phase 3 · combination
1.0 mg/week
nausea 22.2%
diarrhoea 19.2%
vomiting 10.3%
NCT02128932 · Phase 3
0.5 mg/week
nausea 21.3%
diarrhoea 16.3%
nasopharyngitis 12.4%
NCT02128932 · Phase 3
2.0 mg weekly
nausea 14.4%
diarrhoea 9.4%
vomiting 7.7%
NCT03989232 · Phase 3
1.0 mg weekly
nausea 14.6%
diarrhoea 8.8%
vomiting 6.7%
NCT03989232 · Phase 3
1.0 mg weekly
nausea 16.8% (placebo 4.5%)
vomiting 11.5% (placebo 3%)
diarrhoea 6.9% (placebo 1.5%)
NCT02305381 · Phase 3
0.5 mg weekly
nausea 11.4% (placebo 4.5%)
lipase increased 9.1% (placebo 3%)
nasopharyngitis 8.3% (placebo 10.5%)
NCT02305381 · Phase 3
abdominal pain 60%
NCT05786521 · Phase 4 · registry result, not featured evidence
nausea 11.5%
diarrhea 5.8%
NCT05533632 · Phase 4 · registry result, not featured evidence
once weekly
pain 17.5%
upper respiratory infection 0%
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
nausea 19.1%
vomiting 8.5%
upper respiratory tract infection 7.4%
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
nausea 18.4%
diarrhoea 13.5%
vomiting 9.7%
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
7.2 mg
nausea 29% (placebo 11.8%)
diarrhoea 18.2% (placebo 8.8%)
vomiting 16.6% (placebo 2.9%)
NCT05649137 · Phase 3 · registry result, not featured evidence
1.0 mg
covid-19 5.6% (placebo 0%)
decreased appetite 5.6% (placebo 0%)
diabetic retinopathy 5.6% (placebo 5.7%)
NCT04865770 · Phase 3 · registry result, not featured evidence
covid-19 7.6% (placebo 5.3%)
nausea 5.6% (placebo 0.8%)
NCT04560998 · Phase 3 · registry result, not featured evidence
covid-19 14.4%
diarrhoea 12.1%
nausea 11.5%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
nausea 14.8%
diarrhoea 7.4%
nasopharyngitis 6.5%
NCT03689374 · Phase 3 · registry result, not featured evidence
1.0 mg weekly
diarrhoea 16.9%
nausea 13.4%
upper respiratory tract infection 13.1%
NCT03061214 · Phase 3 · registry result, not featured evidence
0.5 mg weekly
diarrhoea 20.2%
upper respiratory tract infection 9.8%
lipase increased 7.7%
NCT03061214 · Phase 3 · registry result, not featured evidence
nausea 22.7%
diarrhoea 15.1%
vomiting 12.8%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
1.0 mg
nausea 21.5%
diarrhoea 15.6%
decreased appetite 10.4%
NCT03191396 · Phase 3 · registry result, not featured evidence
1.0 mg weekly
nausea 19.3% (placebo 3.3%)
diarrhoea 11.3% (placebo 6%)
vomiting 9.3% (placebo 2%)
NCT03086330 · Phase 3 · registry result, not featured evidence
1.0 mg
nausea 21%
diarrhoea 13.7%
vomiting 10.3%
NCT02648204 · Phase 3 · registry result, not featured evidence
0.5 mg
nausea 22.3%
diarrhoea 14.3%
vomiting 10%
NCT02648204 · Phase 3 · registry result, not featured evidence
1.0 mg
nasopharyngitis 31.1%
nausea 19.1%
diarrhoea 15.8%
NCT02207374 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 33.9%
constipation 18.4%
nausea 12.1%
NCT02207374 · Phase 3 · registry result, not featured evidence
1.0 mg
nasopharyngitis 17.6%
nausea 12.7%
constipation 11.8%
NCT02254291 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 16.5%
constipation 14.6%
nausea 10.7%
NCT02254291 · Phase 3 · registry result, not featured evidence
2.0 mg
nausea 21.7% (placebo 15.3%)
vomiting 18.3% (placebo 6.8%)
diarrhoea 15% (placebo 11.9%)
NCT05486065 · Phase 2 · registry result, not featured evidence
16.0 mg
nausea 37.1% (placebo 15.3%)
vomiting 25.8% (placebo 6.8%)
diarrhoea 21% (placebo 11.9%)
NCT05486065 · Phase 2 · registry result, not featured evidence
8.0 mg
nausea 41.7% (placebo 15.3%)
diarrhoea 33.3% (placebo 11.9%)
vomiting 23.3% (placebo 6.8%)
NCT05486065 · Phase 2 · registry result, not featured evidence
21.6 mg
injection site erythema 10.2% (placebo 0%)
injection site reaction 10.2% (placebo 0%)
diarrhoea 8.5% (placebo 11.5%)
NCT05144984 · Phase 2 · registry result, not featured evidence
2.4 mg + 12.0 mg
diarrhoea 14.3% (placebo 11.5%)
constipation 9.1% (placebo 1.6%)
covid-19 7.8% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 2.4 mg
nausea 19.5% (placebo 1.6%)
diarrhoea 14.3% (placebo 11.5%)
covid-19 7.8% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 21.6 mg
diarrhoea 13% (placebo 11.5%)
nausea 13% (placebo 1.6%)
covid-19 11.7% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 7.2 mg
diarrhoea 21.6% (placebo 11.5%)
lipase increased 12.2% (placebo 3.3%)
nausea 12.2% (placebo 1.6%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 43 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Semaglutide (Ozempic)

MACE 3-point Composite 6.6% (n=1648) vs 8.9% (n=1649) placebo
event count · % of participants
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 1 more result
12% (n=1767) vs 14.4% (n=1766) placebo*
NCT03819153 · Phase 3 · converted to % from 212 Participants as posted
HbA1c 6.5 or Less 47% (n=404) vs 22% (n=405) Exenatide ER @ 56wk1.0 mg
event count · % of participants
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 190 Participants as posted
Chronic Dialysis 4.9% (n=1767) vs 5.7% (n=1766) placebo
event rate · % of participants
NCT03819153 · Phase 3 · converted to % from 87 Participants as posted
Renal Death 0.3% (n=1767) vs 0.3% (n=1766) placebo
event count · % of participants
NCT03819153 · Phase 3 · converted to % from 5 Participants as posted
UACR 0.6 vs 0.89 placebo ratio @ 104wk
ratio to baseline · ratio
NCT03819153 · Phase 3
Non-fatal MI 2.9% (n=1767) vs 3.6% (n=1766) placebo
event count · % of participants
NCT03819153 · Phase 3 · converted to % from 52 Participants as posted
MALE 0.9% (n=1767) vs 1.6% (n=1766) placebo
event rate · % of participants
NCT03819153 · Phase 3 · converted to % from 16 Participants as posted
Acute Limb Ischemia 0.1% (n=1767) vs 0.2% (n=1766) placebo @ 234wk
event rate · % of participants
Acute limb ischaemia hospitalization
NCT03819153 · Phase 3 · converted to % from 1 Participants as posted
Chronic Limb Ischemia Hospitalization 0.9% (n=1767) vs 1.4% (n=1766) placebo @ 234wk
event count · % of participants
Chronic limb ischaemia hospitalization
NCT03819153 · Phase 3 · converted to % from 16 Participants as posted
SBP -5.17 vs -1.68 Insulin Glargine mmHg @ 30wk1.0 mg/week
absolute change · mmHg
NCT02128932 · Phase 3
show 13 more results
-4.3 vs -3.7 Liraglutide mmHg @ 30wk1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
-4.3 vs 1.1 placebo mmHg @ 30wk1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
-4.65 vs -1.68 Insulin Glargine mmHg @ 30wk0.5 mg/week
NCT02128932 · Phase 3
-8 vs -3 placebo mmHg @ 72wk7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
-3 vs 0 placebo mmHg @ 34wk21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
-6 vs 0 placebo mmHg @ 34wk2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
-10 vs 0 placebo mmHg @ 34wk2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
-9 vs 0 placebo mmHg @ 34wk2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
-13 vs 0 placebo mmHg @ 34wk2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
-3.9 vs -1.4 placebo mmHg @ 104wk
NCT03819153 · Phase 3
-2.3 vs -1.8 Standard of Care mmHg @ 52wk
NCT03596450 · Phase 4 · registry result, not featured evidence
-3 vs -2.8 Standard of Care mmHg @ 104wk
NCT03596450 · Phase 4 · registry result, not featured evidence
-4 vs -1 placebo mmHg @ 52wk
NCT04560998 · Phase 3 · registry result, not featured evidence
DBP -0.98 vs -1.44 Insulin Glargine mmHg @ 30wk1.0 mg/week
absolute change · mmHg
NCT02128932 · Phase 3
show 7 more results
-1.5 vs -1.3 Liraglutide mmHg @ 30wk1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
-0.1 vs -0.1 placebo mmHg @ 30wk1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
-1.38 vs -1.44 Insulin Glargine mmHg @ 30wk0.5 mg/week
NCT02128932 · Phase 3
-3 vs -3 placebo mmHg @ 72wk7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.8 placebo mmHg @ 104wk
NCT03819153 · Phase 3
-1.6 vs -0.9 Standard of Care mmHg @ 52wk
NCT03596450 · Phase 4 · registry result, not featured evidence
-1.9 vs -1.4 Standard of Care mmHg @ 104wk
NCT03596450 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 72.3% (n=130) vs 24.8% (n=129) placebo @ 30wk1.0 mg weekly
responder rate · % of participants
NCT02054897 · Phase 3
show 10 more results
78.6% (n=131) vs 10.5% (n=133) placebo @ 30wk1.0 mg weekly
NCT02305381 · Phase 3
84% (n=238) vs 49.6% (n=250) Sitagliptin @ 30wk1.0 mg weekly
Yes
NCT03061214 · Phase 3 · registry result, not featured evidence
80.4% (n=290) vs 45.9% (n=287) Liraglutide @ 30wk1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
82.5% (n=120) vs 20.5% (n=127) placebo @ 30wk1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
78.7% (n=300) vs 52.2% (n=299) Dulaglutide @ 40wk1.0 mg
Yes
NCT02648204 · Phase 3 · registry result, not featured evidence
74.2% (n=128) vs 24.8% (n=129) placebo @ 30wk0.5 mg weekly
Yes
NCT02054897 · Phase 3
60.6% (n=132) vs 10.5% (n=133) placebo @ 30wk0.5 mg weekly
NCT02305381 · Phase 3
74.5% (n=235) vs 49.6% (n=250) Sitagliptin @ 30wk0.5 mg weekly
Yes
NCT03061214 · Phase 3 · registry result, not featured evidence
68.4% (n=301) vs 52.2% (n=299) Dulaglutide @ 40wk0.5 mg
Yes
NCT02648204 · Phase 3 · registry result, not featured evidence
76.1% (n=293) vs 50.8% (n=313) Canagliflozin @ 52wk
Yes
NCT03136484 · Phase 3 · registry result, not featured evidence · combination

+ 116 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albenatide's landscape · Semaglutide (Ozempic)'s landscape